✦ LIBER ✦

A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity

✍ Scribed by Ken Hirao; Hirofumi Kawamoto; Ichiro Sakakihara; Yasuhiro Noma; Naoki Yamamoto; Ryo Harada; Koichiro Tsutsumi; Masakuni Fujii; Hironari Kato; Naoko Kurihara; Osamu Mizuno; Tsuneyoshi Ogawa; Etsuji Ishida; Kazuhide Yamamoto

Book ID: 106285420
Publisher: Springer
Year: 2011
Tongue: English
Weight: 348 KB
Volume: 16
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-011-0237-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First line chemotherapy with gemcitabine

First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule

✍ Quoix, Elisabeth; Breton, Jean-Luc; Ducoloné, Alain; Mennecier, Bertrand; Depier 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 155 KB

550 Phase I and pharmacokinetic (PK) stu

550 Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer

✍ S.Q. Chu; G. Schwartz; M. Beeram; A. Patniak; M. Mita; J. Jimeno; L. Lopez-Laraz 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 273 KB

A phase II open-label randomized study t

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 640 KB

Erratum to: A phase II open-label random

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 61 KB

A phase II study of intravenous exatecan

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

✍ Claire F. Verschraegen; Andrzej P. Kudelka; Wei Hu; Monique Vincent; John J. Kay 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 736 KB

Possibility of immunotherapy for biliary

Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial)

✍ Takuji Okusaka, Makoto Ueno, Tosiya Sato, Yuji Heike 📂 Article 📅 2012 🏛 Springer Japan 🌐 English ⚖ 338 KB